Page 322

67. Marchionni MA, Cannella B, Hoban C, et al. 1999. Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligode drocyte progenitor expansion, and enhances remyelination. Adv Exp Med Biol.; 468: 283-295.

68. Marmont A. 1995. Immune ablation followed by stem cell rescue: a new radical approach to the treatment of severe autoimmune diseases. Forum.; 5: 24.

69. McDonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP. 1998. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med.; 4: 291-7.

70. McFarland H, Barkhof F, Antel J, Miller DH. 2001. The role of MRI as a surrogate outcome measure in MS. Ann Neurol.; in press.

71. McKay RD. 1999. Brain stem cells change their identity. Nat Med.; 5: 261-2.

72. Micera A, De Simone R, Aloe L. 1995. Elevated levels of nerve growth factor in the thalamus and spinal cord of rats affected by experimental allergic encephalomyelitis. Arch Ital Biol.; 133: 131-42.

73. Micera A, Lambiase A, Rama P, Aloe L. 1999. Altered nerve growth factor level in the optic nerve of patients affected by multiple sclerosis. Mult Scler.; 5: 389-94.

74. Miller RG, Mitchell JD, Moore DH. 2000. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev.; CD001447.

75. Moore MA. 1999. “Turning brain into blood”—clinical applications of stem-cell research in neurobiology and hematology. N Engl J Med.; 341: 605-7.

76. Morton JI, Siegel BV. 1974. Transplantation of autoimmune potential. I. Development of anti-nuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice. Proc Natl Acad Sci U S A.; 71: 2162-5.

77. Morton JI, Siegel BV. 1979. Transplantation of autoimmune potential. IV. Reversal of the NZB autoimmune syndrome by bone marrow transplantation. Transplantation.; 27: 133-4.

78. Naji A, Silvers W, Bellgrau D, Anderson A, Plotkin S, Bakker C. Prevention of diabetes in rats by bone marrow transplantation. Annals of Surgery. 1981; 194: 328.

79. Nakamura T, Ikehara S, Good RA, et al. 1985. Abnormal stem cells in autoimmune-prone mice are responsible for premature thymic involution. Thymus.; 7: 151-60.

80. Nicolle MM, Shivers A, Gill TM, Gallagher M. 1997. Hippocampal N-methyl-D-aspartate and kainate binding in response to entorhinal cortex aspiration or 192 IgG-saporin lesions of the basal forebrain. Neuroscience.; 77: 649-59.

81. Nudo RJ. 1999. Recovery after damage to motor cortical areas. Curr Opin Neurobiol.; 9: 740-7.

82. Ochs G, Giess R, Bendszus M, Krone A. 1999. Epi-arachnoidal drug deposit: a rare complication of intrathecal drug therapy. J Pain Symptom Manage.; 18: 229-32.

83. Penn RD, Kroin JS, York MM, Cedarbaum JM. 1997. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery.; 40: 94-9; discussion 99-100.

84. Rabchevsky AG, Fugaccia I, Turner AF, Blades DA, Mattson MP, Scheff SW. 2000. Basic fibroblast growth factor (bFGF) enhances functional recovery following severe spinal cord injury to the rat. Exp Neurol.; 164: 280-91.

85. Raine CS. 1996. Multiple sclerosis: prospects for remyelination. Mult Scler.; 2: 195-7.

86. Ransom BR, Waxman SG, Davis PK. 1990. Anoxic injury of CNS white matter: protective effect of ketamine. Neurology.; 40: 1399-403.

87. Register B, Ben-Hur T, Dubois-Dalcq M. 1999. From neural stem cells to myelinating oligodendrocytes. Mol Cell Neurosci.; 14: 287-300.

88. Rose NR, Bona C. 1993. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today.; 14: 426-430.

89. Roubenoff R, Jones RJ, Karp JE, Stevens MB. 1987. Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA. Arthritis Rheum.; 30: 1187-1190.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement